您的位置: 首页 » 法律资料网 » 法律法规 »

吉林省农机事故处理规定

时间:2024-07-04 09:08:17 来源: 法律资料网 作者:法律资料网 阅读:8359
下载地址: 点击此处下载

吉林省农机事故处理规定

吉林省人民政府


吉林省农机事故处理规定


1992年10月26日 吉林省人民政府令第64号


第一章 总 则

   第一条为了正确处理农机事故,保护当事人的合法权益,教育和惩处农机事故责任者,结合我省实际情况,制定本规定。

   第二条本规定所称农机事故是指农用拖拉机、联合收割机、推土机在乡村道路、田间、场院作业、行驶以及在停放中因碰撞、碾压、翻车、落车、火灾造成的事故。

   第三条凡在我省境内发生的农机事故,均依照本规定处理,法律、法规另有规定的除外。

   第四条县以上人民政府的农机主管部门负责处理本行政区域内的农机事故。

   第五条农机管理部门处理农机事故的职责是:处理农机事故现场、认定农机事故责任、处罚农机事故责任者、对损害赔偿进行调解。

   第六条根据人身伤亡或者财产损失的程度和数额,农机事故分为轻微事故、一般事故、重大事故、特大事故。农机事故的划分标准,由省农机主管部门确定。

  第二章 现场处理

   第七条农机发生事故后必须立即停止行驶、作业,当事人必须保护好现场,抢救伤者和财产(必须移动时应标明位置),并及时报告当地农机管理部门听候处理。

   第八条农机管理部门接到事故报告后,要立即派人赶赴现场,组织抢救伤者和财产,勘验现场,收集证据,采取措施尽快恢复交通和生产。

   第九条农机管理部门对造成农机事故的农机、物品、尸体以及当事人的生理和精神状态等有关情况,应当指派专业人员或委托(聘请)国家法定的技术检测、鉴定部门进行检验或者鉴定,并作出书面结论。

   第十条当事人应如实向农机管理部门陈述农机事故发生经过,不得隐瞒事故真实情况。其他知情者有义务向农机管理部门提供有关情况。

   第十一条在追缉农机事故逃逸者或者抢救伤者等紧急情况下,农机管理人员有权使用其他单位或者个人的交通工具和通讯工具,用后立即归还,并应适当付给该车主使用费,对造成损坏的,应当修复或折价赔偿。对肇事逃逸者,公安机关应当协助追缉。

   第十二条农机事故造成人员伤害需要抢救治疗的,农机事故的当事人及所在单位,或者机械的所有者应当预付医疗费,也可由农机管理部门指定一方预付,结案后按照农机事故责任承担。

   第十三条农机管理部门根据事故处理的需要,有权扣留肇事农机、农机牌证和当事人的有关证件。

   第十四条在实行机动车第三者法定保险的行政区域,发生农机事故逃逸案件的,由当地保险公司预付伤者抢救期间的医疗费,死者丧葬费。保险公司有权向抓获的逃逸者及其所在单位或者农机的所有者,追偿其预付的所有款项。

   第十五条医疗单位应当及时抢救治疗农机事故的伤者,并如实向农机管理部门提供医疗单据和诊断证明。

   殡葬服务单位和有停尸条件的医疗单位,对农机管理部门决定存放的农机事故中死者的尸体,应当接受代存。要求殡葬服务单位和医疗单位停存尸体时,应出示死亡证明。

   农机管理部门,应当协助上述单位收取抢救医疗费和尸体存放费用。

   第十六条农机管理部门对农机事故死亡的尸体进行检验鉴定后,应当通知死者家属在十日内办理丧葬事宜。逾期不办理的,经县以上农机管理部门负责人批准,尸体由农机管理部门处理,逾期存放尸体的费用由死者家属承担。

   第十七条农机管理人员在勘验事故现场时应佩带农机监理标志,并出示《农机事故现场勘察证》。

  第三章 责任认定

   第十八条农机管理部门在查明农机事故原因后,应当根据当事人的违章行为与农机事故之间的因果关系,以及违章行为在农机事故中的作用,认定当事人的事故责任。当事人有违章行为,其违章行为与农机事故有因果关系的,应当负农机事故责任;违章行为与农机事故无因果关系的,不负农机事故责任。

   第十九条农机事故的责任分为全部责任、主要责任、同等责任、次要责任四种。

   第二十条完全由一方当事人违章造成的事故,由违章行为的一方负全部责任,其他一方不负事故责任。

   由双方当事人的违章行为共同造成的农机事故,违章行为在事故中作用大的一方负主要责任,另一方负次要责任;违章行为在事故中作用基本相当的,双方负同等责任。

   三方以上当事人的违章行为共同造成农机事故的,根据各自的违章行为在事故中的作用大小划分责任。

   第二十一条发生农机事故后,当事人逃逸或者故意破坏、伪造现场、毁灭证据,使事故责任无法认定的,应当负全部责任。

   当事人各方有条件报案均未报案或未及时报案,使农机事故责任无法认定的,应当负同等责任;当事人一方有条件报案,而未报案或未及时报案,使事故责任无法认定的,有条件报案的一方应当负全部责任。

   第二十二条当事人对农机事故的责任认定不服的,可以在接到农机事故责任认定书后十五日内,向上一级农机管理机关申请重新认定,上一级农机管理机关在接到重新认定申请书后三十日内,应当作出维持、变更或者撤消的决定。

  第四章 罚 则

   第二十三条对造成农机事故的责任者需要给予治安处罚和追究刑事责任的,由公安、司法机关依法处理。其中对依法追究刑事责任的驾驶员,应当吊销其驾驶证。

   第二十四条造成农机事故尚不够处罚和治安处罚的责任者,按以下规定处罚:

   (一)对特大事故负次要责任以上的,重大事故负同等责任以上的事故责任者,处一百元以上一百五十元以下罚款;

   (二)造成重大事故负次要责任的,处八十元以上一百元以下罚款;

   (三)造成一般事故负同等责任以上的处五十元以上七十元以下罚款;

  (四)造成一般事故负次要责任的处二十元以上四十元以下罚款;

  (五)造成轻微事故,负有事故责任的处十元以下罚款或警告。

  对前款第一项的农机驾驶员,可并处吊销驾驶证;对前款第二项至第四项的农机驾驶员,可并处吊扣农机驾驶证一至四个月。

   第二十五条发生农机事故后,驾驶员有下列行为之一的,并处吊销驾驶证。

  (一)逃逸;

  (二)破坏、伪造现场、毁灭证据;

  (三)隐瞒农机事故真相;

  (四)嫁祸于人;

  (五)其他恶劣行为。

   第二十六条吊销驾驶证从裁决之日起生效。被吊销驾驶证的,两年内不准重新申请领取驾驶证。

   第二十七条农机管理部门处罚农机事故责任者时,应当制作裁决书,分别送交当事人、被处罚人或当事人的工作单位和被处罚的机具驾驶员现籍管理部门。

   第二十八条当事人对处罚不服的可在接到处罚裁决书后十五日内向上一级农机管理部门申请复议,上一级农机管理部门在接到复议申请书后三十日内应作出复议决定。当事人对复议决定不服的,可以在接到复议裁决书后十五日内向人民法院提起行政诉讼。

  第五章 调 解

    第二十九条农机管理部门应在查明农机事故原因、认定事故责任、确定农机事故造成的损失情况后,召集当事人和有关人员对损害赔偿进行调解。

    第三十条损害赔偿调解期限为三十天,农机管理部门认为必要时可以延长十五天。因农机事故致伤的,调解以治疗终结或者定残之日起开始;因农机事故致死的,调解从规定办理丧葬事宜结束之日起开始;对农机事故仅造成财产损失的,调解从确定损失之日起开始。

   第三十一条经调解达成协议的,农机管理部门应当制作调解书,由当事人和有关人员、调解人签名、并加盖农机管理部门印章后即行生效。农机管理部门应当将调解书分别送交当事人和有关人员。

    调解期满未达成协议的,农机管理部门应当制做调解终结书,由调解人签名并加盖农机管理部门印章后,分别送交当事人和有关人员。

   第三十二条经调解未达成协议或者调解书生效后一方不履行的,农机管理部门不再调解,当事人可以向人民法院提起民事诉讼。

  第六章 损害赔偿

    第三十三条农机事故责任者应当按照所负农机事故责任,承担相应的损害赔偿。

    第三十四条损害赔偿包括医疗费、误工费、住院伙食补助费、护理费、残疾者生活补助费、残疾用具费、丧葬费、死亡补偿费、被抚养人生活补助费、交通费、住宿费和财产直接损失。

   前款规定的赔偿项目应当按照实际情况确定,并一次性结算费用。

   第三十五条事故的损害赔偿费,由事故责任者依照其所负的责任,按下列比例承担:(一)负全部责任,承担100%;(二)负主要责任,承担60%--90%;(三)负同等责任的,各承担50%;(四)负次要责任的,承担20%--40%。

   第三十六条损害赔偿标准按下列规定计算:(一)医疗费:按照医院对当事人因事故而致创伤治疗所必须的费用计算,凭据支付。(二)误工费:当事人有固定收入的,按照本人因误工而减少的固定收入计算,但固定收入高于农机事故发生地平均生活费三倍以上的按三倍计算;无固定收入的,可按照当事人因误工减少的实际收入酌定。(三)住院伙食补助费:按国家机关工作人员出差补助最低标准计算。(四)就医路费:按实际必须的费用凭据支村。乘软卧和飞机时,须事先经农机管理部门同意。(五)护理费:伤者住院期间,护理人员因护理病人而误工的,其误工费的计算方法为,护理人员有固定收入的,按其实际固定收入减少部分计算;无收入的,按照农机事故发生地平均生活费计算。护理人员以医院批准的人数为限。(六)住宿费:按照农机事故发生地国家机关一般工作人员出差规定的最低住宿标准计算,凭据支付。(七)丧葬费:按照农机事故发生地有关部门规定的丧葬费标准计算,最高不超过四百元。(八)残疾者生活补助费:按照农机事故发生地平均生活费计算。根据伤残等级,赔偿期为五年至二十年。五十周岁以上的,年龄每增加一岁,补偿年限减少一年,最低不少于五年。(九)残疾用具费:致残需要配制假肢、代步车、拐杖等补偿功能器具的,凭医院证明按照普及型的费用计算。(十)死亡补偿费:按照农机事故发生地平均生活费计算,补偿十年。对不满十六周岁的,年龄每小一岁减少一年;对七十岁以上的,年龄每增加一岁减少一年。补偿最低不少于五年。(十一)被供养人的生活补助费:以死者生前或者丧失劳动能力前实际抚养的、没有其他生活来源的人为限,被抚养人的生活补助费以农机事故发生地居民生活困难补助标准计算。对不满十六周岁的抚养到十六周岁。对无劳动能力的抚养二十年,但五十周岁以上的,年龄每增加一岁减少一年,最低不少于十年;七十周岁以上的按五年计算。对其他的被抚养人抚养五年。

   第三十七条参加处理农机事故的当事人亲属所需交通费、误工费、住宿费参照第三十六条的规定执行,按照当事人的事故责任分担,但参加人数不得超过三人。

   第三十八条农机事故的伤者需要住院、转院,应当有医院证明,并经农机管理部门同意;擅自住院、转院、自购药品、增加护理人员或者超过医院通知的出院日期拒不出院的,费用自理。

   根据工作需要,农机管理部门有权到医院调查事故伤残者的治疗情况,医院应协助配合。

   第三十九条因农机事故损坏的机具、物品、设施等,应当以修复为主,不能修复的折价赔偿。造成牲畜伤亡的或使之失去使用价值的,折价赔偿。

   第四十条农机事故的责任者构成犯罪,使国家、集体财产遭受损失的,由农机管理部门根据肇事者对事故承担的责任提出赔偿意见,随同案件移送人民检察院,依法提起附带民事诉讼。公民因农机事故的责任者构成犯罪而受财产损失的可以依法提起附带民事诉讼。

  第七章 其他规定

    第四十一条农机事故的当事人因伤致残的,在治疗终结后十五日内可以向农机管理部门申请伤残评定。农机管理部门应当根据医院证明并参照省有关伤残评定标准进行评定。评定工作应在接到申请书后三十日内完成。当事人对评定伤残定级不服的,可在接到通知书十五日内,向上一级农机管理部门申请重新评定。上一级农机管理部门在接到申请书后三十日内,应当作出重新评定决定。

   第四十二条职工因农机事故致死、致残丧失劳动能力的,按本办法处理后,职工所在单位还应按照有关规定给予抚恤、劳动保险待遇。

   第四十三条农业机械与非机动车、行人发生农机事故,造成对方人员死亡或者重伤的,农业机械一方虽无过错,也应当分担对方10%的经济损失,但按照10%计算赔偿超过事故发生地十个月平均生活费的,按十个月平均生活费支付。前款非机动车一方、行人、农机生产辅助人员故意造成自身伤害的除外。

   第四十四条农机事故的人身伤亡或者财产损失,经农机管理部门调查不能确认是任何一方当事人违章行为造成的,其损害纠纷当事人可以向人民法院提起民事诉讼。

   第四十五条农机管理部门对检举和协助追查农机事故逃逸者的有关人员,应当予以表彰或者奖励。

  第八章 附 则

   第四十六条本规定下列术语含意: (一)“乡村道路”,是指公路行政主管部门依法管理的公路以外连接县、乡、村之间的道路。(二)“有固定收入的”,包括非农业人口中有固定收入的和农业人口中有固定收入的两部分。非农业人口中有固定收入的,是指在国家机关、企事业组织、社会团体等单位按期得到收入的,其收入包括工资、奖金及国家规定的补贴、津贴。奖金以农机事故发生时上一年度本单位人均奖金计算,超出奖金税计征起点的,以计征起点为限。农业人口中有固定收入的,是指直接从事农、林、牧、渔业的在业人员,其收入按照农机事故发生地劳动力人均年纯收入计算。(三)“无固定收入的”,是指在农机事故发生前从事某种劳动,其收入能维持本人正常生活的。(四)“无收入的”,是指本人生活来源主要或者全部依靠他人供给,或者偶然有少量收入,但不足以维持本人正常生活的。(五)“平均生活费”,是指农机事故发生地人民政府统计部门公布的上一年度城镇居民家庭人均生活费支出额,或者农民家庭人均生活消费支出额。

    第四十七条本规定以外的农业机械发生农机事故,可参照本规定执行。

    第四十八条本规定由吉林省人民政府法制局负责解释。

    第四十九条本规定自发布之日起施行。在本办法施行以前发生的农机事故,仍按照原规定执行。


Provisions for Drug Insert Sheets and Labels

Commissioner of SFDA


Provisions for Drug Insert Sheets and Labels



(SFDA Decree No.24)

The Provisions for Drug Insert Sheets and Labels, adopted at the executive meeting of the State Food and Drug Administration on March 10, 2006, is hereby promulgated and shall go into effect as of June 1, 2006.


Shao Mingli
Commissioner of SFDA

March 15, 2006





Provisions for Drug Insert Sheets and Labels


Chapter I General Provisions

Article 1 The Provisions are enacted with a view to regulating drug insert sheets and labels in accordance with the Drug Administration Law of the People’s Republic of China and the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China.

Article 2 The insert sheets and labels of drugs marketed within the territory of the People’s Republic of China shall meet the requirements of the Provisions.

Article 3 Drug insert sheets and labels shall be reviewed and approved by the State Food and Drug Administration.

A drug shall be labeled on the basis of its insert sheet. The content of the label shall be within the scope of the insert sheet. Any words and marks with implied therapeutic effects, misleading information on usage, or inappropriate promotion of the product shall not be printed.

Article 4 A drug label shall be printed on or affixed to the drug package, and no other written words, audio and/or visual materials or other information are attached to introduce or publicize the product or the enterprise.

An insert sheet shall be attached to the smallest package provided by the drug manufacturer for marketing.

Article 5 The wording in drug insert sheets and labels shall be scientific, standardized and accurate. The insert sheet of a non-prescription drug shall be written intelligibly and convenient for patients to judge, choose and use the drug on their own.

Article 6 In the label or insert sheet, the letters or characters shall be clear and easy to be recognized and the marks shall be clear and distinctive. The label and insert sheet shall have no print faded and shall not be affixed unsteadily. Any addition or modification shall not be made by means of pasting, cutting or altering.

Article 7 Drug insert sheets and labels shall be written in standardized Chinese characters published by the National Language Commission. The versions in other languages shall comply with the Chinese version.

Article 8 With the aim to protect public health and direct the rational use of drugs, drug manufacturers may voluntarily apply to add warnings to drug insert sheets or labels. The State Food and Drug Administration may also request drug manufacturers to add warnings to drug insert sheets or labels.


Chapter II Drug Insert Sheet

Article 9 A drug insert sheet shall include the significant scientific data, conclusions and information concerning drug safety and efficacy in order to direct the safe and rational use of drugs. The specific format, content and writing requirements of drug insert sheet shall be prescribed and issued by the State Food and Drug Administration.

Article 10 Disease names, pharmaceutical terms, drug names, the names and results of clinical testing in drug insert sheets shall be expressed in professional terms published or standardized by the State. The units of measurement shall conform to the national standards.

Article 11 All the active ingredients or medicinal ingredients of traditional Chinese medicines in a prescription shall be listed in the insert sheet. For injections and non-prescription drugs, all excipients shall be listed as well.

The ingredients or excipients included in a prescription, which may cause severe adverse reaction, shall be specified.

Article 12 A drug manufacturer shall trace the safety and efficacy of its marketed drugs. For any modification to the insert sheet, an application shall be submitted timely.

The State Food and Drug Administration may also require a drug manufacturer to make modification to the insert sheet on the basis of the results of adverse drug reaction monitoring and drug re-evaluation.

Article 13 After the modification to the insert sheet is approved, the drug manufacturer shall inform relevant drug distributors, drug users and other departments of the modified content immediately, and use the modified insert sheet and label timely as required.

Article 14 The insert sheet shall provide full information on adverse drug reaction and indicate the adverse reactions in detail. A drug manufacturer, who fails to timely modify the insert sheet on the basis of the safety and efficacy data of the marketed drug or to fully explain the adverse reaction in the insert sheet, shall be liable for all the consequences arising therefrom.

Article 15 The approval date and the modification date shall be distinctively shown in the insert sheet.


Chapter III Drug Labels

Article 16 Drug labels refer to the information printed or pasted on drug packaging, including inner labels and outer labels. Inner labels refer to those that appear on immediate packaging; outer labels are those on the other packaging outside of inner labels.

Article 17 The inner label shall bear such drug information as the adopted name in China, indications or functions, strength, dose and usage, production date, batch number, expiry date and manufacturer. If there is no enough space in the package to include all the information mentioned above, the adopted name in China, strength, batch number and expiry date shall be indicated at least.

Article 18 The outer label of a drug shall indicate such information as the adopted name in China, ingredients, description, indications or functions, strength, dose and usage, adverse reactions, contraindications, precautions, storage, production date, batch number, expiry date, approval number and manufacturer. Where indications or functions, dose and usage, adverse reactions, contraindications and precautions cannot be fully noted, main information plus a “See drug insert sheet for details.” notice shall be indicated.

Article 19 The label on the package for transportation and storage shall bear at least the adopted name in China, strength, storage, production date, batch number, expiry date, approval number and manufacturer. Other information such as packaging quantity, precautions for transportation or other marks may be included when necessary.

Article 20 The label for drug substance shall include the adopted name in China, storage, production date, batch number, expiry date, applied specifications, approval number and manufacturer. Other necessary information such as packaging quantity and precautions for transportation shall also be indicated.

Article 21 Where one drug produced by a manufacturer has the same drug strength and packaging specification, the content, format and color of its labels must be the same. Where one drug produced by a manufacturer has different drug strengths or packaging specifications, its labels shall be clearly distinguished from one another, or its specifications shall be notably marked in the corresponding specification items.

Where a drug produced by a manufacturer is administrated as prescription drug and non-prescription drug respectively, their packaging colors shall be distinctly different.

Article 22 For drugs with special requirements on storage, its requirements shall be marked in the notable place of the label.

Article 23 The expiry date in the drug label shall appear in the order of year, month and day, with year shown in four digits, month and day in two digits. Its specific format shall be “Valid till XXXX year XX month” or “Valid till XXXX year XX month XX day”. It may be presented with numbers and other symbols as “Valid till XXXX.XX.” or “Valid till XXXX/XX/XX”.

For the preventive biological product, the expiry date shall be labeled according to the registration specifications approved by the State Food and Drug Administration. The expiry date of the biological product for therapeutic use shall be counted from the filling date. For other drugs, the expiry date shall be counted from the production date.

Where the expiry date is labeled to the day, it shall be marked as one day earlier than the actual expiry date; where the expiry date is labeled to the month, it shall be marked as one month earlier than the actual expiry month.


Chapter IV Use of Drug Name and Registered Trademark

Article 24 The drug name in insert sheets and labels shall conform to the nomenclature principles on the adopted name in China and trade name of drug announced by the State Food and Drug Administration, and shall be consistent with those appeared in the approval documents of the drug.

Article 25 The adopted name in China shall be conspicuous and prominent, and its typeface, size and color shall be consistent, and meet the following requirements:
(1) For horizontal labels, the adopted name in China shall appear in a prominent position within the area of the upper one-third of the label; for vertical labels, it shall appear in a prominent position within the area of the right one-third of the label;
(2) No such illegible typefaces as cursive characters and seal characters shall be used, and no such format as italics, margining and shading shall be used to modify the typefaces.
(3) The font color of the adopted name in China shall be black or white, in sharp contrast to the light-colored or dark-colored background respectively.
(4) Writing in separate lines shall be avoided unless limited by the packaging size.

Article 26 The trade name of a drug shall not be placed in the same line with the adopted name in China; its typeface and color shall be no more conspicuous than that of the adopted name in China, and its font area per character shall be no bigger than half of that of the adopted name in China.

Article 27 Unregistered trademarks and other drug names unapproved by the State Food and Drug Administration shall not be used in the drug insert sheets and labels.

Where a registered trademark is used in a drug label, it shall be printed in a corner of the label. Where a registered trademark contains characters, the font area per character shall be no bigger than a quarter of that of the adopted name in China.


Chapter V Other Provisions

Article 28 For narcotic drugs, psychotropic substances, medicinal toxic drugs, radioactive pharmaceuticals, drugs for topical use, non-prescription drugs and other drugs having special marks specified by the State, their special marks shall be printed in the drug insert sheets and labels.
Where there are special provisions issued by the State for drug insert sheets and labels, they shall prevail.

Article 29 The labeling provisions for Chinese crude drugs and prepared slices of Chinese crude drugs shall be formulated separately by the State Food and Drug Administration.

Article 30 Where drug insert sheets and labels are not in compliance with the Provisions, a punishment shall be imposed in accordance with the relevant provisions of the Drug Administration Law of the People’s Republic of China.


Chapter VI Supplementary Provisions

Article 31 These Provisions shall come into force as of June 1, 2006. the Provisions for Drug Packaging, Labels and Insert Sheets (Provisional) issued by State Food and Drug Administration on October 15, 2005 shall be annulled therefrom.


全国人民代表大会常务委员会公告〔十一届〕第一号

全国人民代表大会常务委员会


全国人民代表大会常务委员会公告

〔十一届〕第一号

第十一届全国人民代表大会代表李天军因病去世,李天军的代表资格自然终止。

全国人民代表大会常务委员会对李天军代表的去世表示哀悼。

特此公告。

全国人民代表大会常务委员会

2008年6月26日